A strategy based on three key assets
Predilife is focusing its efforts on three main assets. MammoRisk in Europe is undergoing a clinical study with a publication timeline of around 18 months, considered sufficient to attract potential industrial partners. In the United States, the FDA submission for DenSeerisk, which includes MammoRisk, is ongoing. In parallel, the predictive multi-pathology tests for corporate health assessments have shown their commercial viability, with over 10,000 covered employees and agreements reached with major brokers and large companies in various sectors.
Reorganization and cash flow horizon
The internal activity of tests for employees, currently unprofitable, will be stopped as part of a restructuring planned for mid-April 2026. This measure will result in a significant reduction of the workforce involved and aims to limit the monthly cash consumption. After receiving the research tax credit in 2025, the company’s cash flow will be around 300 kE with an estimated cash burn of 40 kE per month, providing a cash flow horizon until December 2026. The company will release its 2025 annual results no later than May 15, 2026, and its annual financial report no later than May 30, 2026.
